Immatics (IMTX) Stock Price, News & Analysis

Company Overview

Immatics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, the company uses its target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells.

Its pipeline includes engineered T-cell receptor (TCR) T-cell therapies, which modify a patient’s T cells to recognize specific tumor targets, as well as TCR bispecific therapies designed to connect T cells with cancer cells. Immatics’ research focuses on targets derived from proteins inside tumor cells that can be presented on the cell surface.

The company has operations in Europe and the United States, including locations in Germany and Houston, Texas. Immatics is a research and development company, with its work centered on advancing its oncology therapies through clinical development.

Key Stats

• Today's Range: $6.35 to $6.81
• 50-Day Range: $6.18 to $9.56
• 52-Week Range: $6.09 to $12.41
• Volume: 964,299 shs
• Average Volume: 1.20 million shs
• Market Capitalization: $914.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.00
• Consensus Rating: Moderate Buy

Immatics Stock Analysis - MarketRank™

Immatics scored higher than 64% of companies evaluated by MarketBeat, and ranked 307th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immatics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Immatics has a consensus price target of $19.00, representing about 184.0% upside from its current price of $6.69.

Amount of Analyst Coverage

Immatics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immatics are expected to decrease in the coming year, from ($1.99) to ($2.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immatics is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immatics is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immatics has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.68% of the float of Immatics has been sold short.

Short Interest Ratio / Days to Cover

Immatics has a short interest ratio ("days to cover") of 3.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Immatics has recently decreased by 2.09%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immatics does not currently pay a dividend.

Dividend Growth

Immatics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.31

News Sentiment

Immatics has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Immatics this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $7,499,991.00 in company stock, which represents 0.8202% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Immatics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,499,991.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

3.30% of the stock of Immatics is held by insiders.

Percentage Held by Institutions

64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMTX
• CIK: 1809196
• Web: www.immatics.com
• Phone: 4.97072E+12
• Fax: N/A
• Employees: 704
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Immatics: $19.00
• High Price Target: $25.00
• Low Price Target: $15.00
• Potential Upside/Downside: +184.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$222.26 million
• Net Margins: -533.26%
• Pretax Margin: -495.98%
• Return on Equity: -52.27%
• Return on Assets: -43.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.54
• Quick Ratio: 7.54

Sales & Book Value

• Annual Sales: $43.44 million
• Price / Sales: 21.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.09 per share
• Price / Book: 1.64

Miscellaneous

• Outstanding Shares: 136,690,000
• Free Float: 132,179,000
• Market Cap: $914.46 million
• Optionable: Optionable
• Beta: 1.38